Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Renalpharma
Suzhou, Jiangsu, Chinarenalpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RenalPharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing and commercializing innovative therapies for chronic kidney disease (CKD) and its complications. The company's strategy focuses on licensing late-stage assets for the Chinese market alongside internal R&D efforts. Its lead program, Kiklin (RP-101), is a non-calcium, non-metal phosphate binder licensed from Sanwa Kagaku Kenkyusho, currently in Phase 3 trials for hyperphosphatemia. RenalPharma is also developing Enaroy (RP-601), an oral HIF-PH inhibitor licensed from Japan Tobacco for the treatment of renal anemia, which is also in Phase 3 development. Backed by prominent investors such as Lilly Asia Ventures and Matrix Partners China, the company is positioned as a leader in the specialized nephrology space in China.
- Therapeutic areas
- Nephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Japan TobaccoSanwa Kagaku Kenkyusho
Beyond the preview
Go deeper on Renalpharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renalpharma.